Previous pre-clinical studies demonstrated that exogenous administration of recombinant human wild type BMP9 (WT BMP9) enhances BMPR2/ALK1 mediated signaling and reverses experimental pulmonary hypertension in rat models. Here, BMPR2 is linked to pulmonary arterial hypertension.